Why Catalent Inc. Rose as Much as 17% This Morning
Shares of drug-delivery technology specialist Catalent (NYSE: CTLT) jumped as much as 17% Tuesday morning in the wake of the company's 2017 fiscal year earnings report, released Monday after the market closed. As investors can probably guess, it was a pretty good 12 months. But management expects the next 12 months will be even better.
In addition to strong business momentum financially speaking, Catalent reported that it had entered into a long-term supply agreement to produce the next-generation OTC pain relief product from Pfizer, Advil Liqui-Gels Minis. It's just the latest indication that its growth won't be stopping anytime soon. As of 11:30 a.m. EDT, the stock had settled to a 15% gain.
Image source: Getty Images.
Source: Fool.com
Pfizer Inc. Stock
€27.07
-0.170%
Currently there is a rather positive sentiment for Pfizer Inc. with 27 Buy predictions and 5 Sell predictions.
With a target price of 40 € there is a positive potential of 47.79% for Pfizer Inc. compared to the current price of 27.07 €.
